Anthrax vaccine showdown as PharmAthene’s SparVax Phase II gets FDA go ahead

PharmAthene have announced that the FDA has lifted the clinical hold previously placed on the Phase II study of it's next generation anthrax vaccine, SparVax. The FDA had originally placed a hold on the trial back in August 2012, requesting that PharmaAthene "provide additional stability data for both its engineering and GMP lots of U.S. manufactured Final Drug Product, as …